2019 Dates Confirming Soon | Boston, MA



Expertise Partner

ANGLE’s Parsortix technology enables the capture and harvest of circulating tumor cells from patient blood. The resulting liquid biopsy (simple blood test) provides a powerful tool to deliver personalized cancer care. ANGLE is currently developing its first diagnostic product in the area of ovarian cancer. The Parsortix system has CE Mark regulatory approval in Europe and an FDA approval process is underway in the US.




Expertise Partner

MolecularMD develops and commercializes specialty diagnostics for oncology applications. Tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD integrates proven and innovative platform technologies with clinical assay design, validation, and centralized testing to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. MolecularMD’s core competency is in streamlining the development, regulatory approval, and clinical deployment of precision oncology medicines. The company provides customized Clinical Trial Assay and CDx development in their CAP-accredited, CLIA-certified laboratories in Portland, Oregon and Cambridge, Massachusetts.



Expertise Partner

NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-licensed facilities across the U.S., but work hard to maintain easy access and all the efficiencies of a smaller operation.



Expertise Partner

Diaceutics is the diagnostic development and commercialization service provider. We have been leading this field for 13 years, entirely focused on the intersection between diagnostics and therapeutic decision making. We provide an end to end service that encompasses everything from understanding the diagnostic landscape to test implementation in treatment pathways. This is all enabled by a robust flow of data from our global laboratory network. Our ultimate goal is to drive better testing to enable better treatment decisions for patients.


Q2 Solutions

Expertise partner

Q2 Solutions is a leading global clinical trials laboratory services organization that partners with biopharmaceutical, medical device and diagnostics customers to transform science and data into actionable medical insights. Its laboratory services span the development lifecycle from Discovery through Clinical Trials to Commercialization that includes predictive biomarker solutions for Companion Diagnostics.


Quest Diagnostics

Expertise Partner

Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.  Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.




Almac Diagnostics

Program Partner

Almac Diagnostics is a stratified medicine company specialising in biomarker driven clinical trials. Our diagnostic experience spans oncology, immunology, CNS and infective diseases. Our global laboratories, based in the UK and US offer tailored solutions from discovery to commercialisation: Biomarker discovery. Custom assay development & validation. DNA and RNA panel solutions. Flexible CDx development & commercialisation. Expert regulatory support. Bioinformatics & software development. Your Clinical Trial Diagnostic Partner.




Program Partner

Corgenix is a global diagnostics company that commercializes Immunoassay IVDs for autoimmune, cardiovascular and liver diseases. Additionally, Corgenix has more than 20 years’ experience in contract Immunoassay development and manufacturing, serving the needs of Pharma and Diagnostic companies. Our Personalized Diagnostics Team collaborates with Pharma and other Personalized Medicine stakeholders to develop and commercialize companion diagnostics. Our newly established CLIA laboratory allows for better management of the assay development process and provides more options for our Partners.




Program Partner

Biocartis aims to provide direct access to personalized medicine for patients worldwide by developing fully integrated and broadly applicable molecular diagnostics. Our platforms can be used in a wide variety of healthcare settings to enable rapid and high-quality care close to patients.




Program Partner

Ultivue is a venture-backed company developing reagent-driven solutions for high-performance biological imaging in situ, combining unlimited multiplexing at high speed with high spatial resolution. Ultivue’s proprietary solutions will enable researchers to realize the promise of personalized medicine. The company has launched products and services that will seamlessly integrate into existing workflows for biomarker discovery, assay validation, and companion diagnostic applications.



Program Partner

Unilabs is a leader in Companion Diagnostic testing in Europe with several years of experience with the associated necessary global, customized logistics & regulatory know-how.

Unilabs is Serving Pharma as a highly customer centric and specialized bioanalytical laboratory service partner with structured processes to reduce budget risks & stalling of drug development.

Unilabs has more than 8.000 employees, and more than 30 years of clinical trials experience, handling more than 3.000 studies involving a broad range of matrices from numerous species and in a vast number of therapeutic areas.



Program Partner

Enabling higher multiplexing for real-time PCR instruments. Leveraging digital signal processing to provide higher efficiency and lower costs for our laboratory customers. ChromaCode is deploying a disruptive solution for mid-density, multiplexed analysis, high-definition PCR or HDPCR​ , exclusively licensed from the California Institute of Technology.



Program Partner

Invivoscribe is the worldwide leader in precision medicine and companion diagnostics (CDx) for hematological malignancies. Invivoscribe offers a full range of hematology-oncology testing products and services (B- and T-cell clonality, NGS gene panels, MRD assays, and comprehensive bioinformatics software), all developed under ISO 13485 design control and manufactured in our own cGMP facility. We also operate the Laboratories for Personalized Molecular Medicine (LabPMM), a global network of clinical reference labs with locations in the United States, Germany, and Japan. These laboratories offer an ever-expanding menu of internationally harmonized tests to support the stratification and enrollment of patients in clinical trials, optimized treatments, and development of CDx. We continually strive to provide access to accurate test results and improve the quality of healthcare worldwide



Program Partner

Mitra Biotech is a global leader in advancing personalized oncology treatment and supporting more effective and efficient cancer drug development. Founded in 2010, Mitra is headquartered in Greater Boston and maintains a significant research and laboratory presence in Bengaluru, India.





Panel Partner

We improve patient lives by unlocking the tissue phenome. Our work model builds on a simple premise: Tissue Phenomics strengthens results, from biomarker discovery to clinical development and meaningful diagnostics. We bring Tissue Phenomics to you, seamlessly integrate into your processes, and act as your reliable, science-driven partner along the way.



Flagship Biosciences

Spotlight Partner

Flagship Biosciences helps drug developers confidently define their path to success. Our Computational Tissue Analysis (cTA™) platform provides the quantitative, contextual tissue interpretation necessary to make timely decisions.

With a unique combination of our technology platform, extensive expertise across multiple disciplines (e.g., pathology, biology, image analysis, software engineering), and an in-house CLIA lab, Flagship Biosciences develops quantitative tissue biomarker interpretations for clinical development of tissue-based diagnostics, including companion diagnostics (CDx). We collaborate with biopharmaceutical teams at every stage of the clinical trial to:

  • Make informed pipeline decisions that will accelerate the right clinical path
  • Enable critical go/no go decisions based on confirmation of action
  • Design, implement and evaluate prototype diagnostic strategies
  • Differentiate commercial strategies to increase probability of success

Over 100 pharmaceutical, biotech, and medical device firms rely on Flagship’s technology for success. As the largest clinical tissue-image-analysis operation in the US, Flagship has completed over 400 projects since 2009.


For further information please don’t hesitate to send us an email.